Patents Issued in February 18, 2014
  • Patent number: 8653006
    Abstract: Methods for the detection and screening of esophageal adenocarcinoma (EAC) patients and for the monitoring of EAC treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. In other aspects, methods for detection and screening for the progression of high-risk conditions (BE and HGD) to EAC and to monitoring treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. The biomarkers are sensitive and specific for the detection of EAC, and can also be used to classify Barrett's esophagus (BE) and high-grade dysplasia (HGD), which are widely regarded as precursors of EAC.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: February 18, 2014
    Assignee: Purdue Research Foundation
    Inventors: M. Daniel Raftery, Jian Zhang, Zane Hammoud
  • Patent number: 8653007
    Abstract: Compositions, methods and related uses are provided relating to cleaving modified DNA. For example, a set of DNA fragments obtainable by enzymatic cleavage of a large DNA is described where at least 50% are similarly sized and have a centrally positioned modified nucleotide. In addition, an enzyme preparation is provided that includes one or more enzymes that recognize a modified nucleotide in a DNA and cleave the DNA at a site that is at a non-random distance from the modified nucleotide. The one or more enzymes are further characterized by an N-terminal conserved domain with greater than 90% amino acid sequence homology to WXD(X)10YXGD. The related uses include creating a methylome, methods of purifying DNA fragments containing a modified nucleotide and diagnostic applications.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: February 18, 2014
    Assignee: New England Biolabs, Inc.
    Inventors: Yu Zheng, Richard J. Roberts
  • Patent number: 8653008
    Abstract: A method for delivering a scale treatment agent to a hydrocarbon producing system. The method includes the steps of contacting the system with a foam comprising the scale treatment agent, and shutting the scale treatment agent in the system for at least 0.5 hour.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: February 18, 2014
    Assignees: Champion Technologies Ltd., Halliburton Energy Services, Inc., StatoilHydro ASA
    Inventors: Olav Martin Selle, Amare Mebratu, Harry Montgomerie, Ping Chen, Thomas Hagen
  • Patent number: 8653009
    Abstract: The invention relates to the use of compounds comprising three hydrophobic groups as additives to a stream of crude oil containing carboxylic acids, in particular naphthenic acids, and salt water, to prevent the formation of calcium carboxylates when the fluid is exposed to shear forces. Preferably, the compounds are added to a crude oil/water stream containing organic acids Ca2+ ions at a point between the well and the pressure reduction valve in the crude oil receiving station.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: February 18, 2014
    Assignee: AKZO Nobel N.V.
    Inventors: Martin Hellsten, Ingemar Uneback
  • Patent number: 8653010
    Abstract: Novel uses of reactive surfactants in treating subterranean formations and/or proppant particulates are provided. In one embodiment, the present invention provides a surfactant-treated proppant particulate comprising a proppant particulate that comprises at least one surface that has been allowed to interact with a reactive surfactant.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: February 18, 2014
    Assignee: Halliburton Energy Services, Inc.
    Inventors: Thomas D. Welton, Philip D. Nguyen
  • Patent number: 8653011
    Abstract: A gelled organic-based fluid system and method of forming and using the system. The fluid system is prepared by gelling an organic solvent, a viscoelastic surfactant, and a nitrogen compound having a free electron pair such as urea in an amount effective to both increase viscosity and increase a rate of breaking the viscosity, relative to the gelled system without the nitrogen compound. In a further aspect, the method is used to treat a well penetrating a subterranean formation, for example, in a coiled tubing cleanout, or the like.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: February 18, 2014
    Assignee: Schlumberger Technology Corporation
    Inventors: Mathew M. Samuel, Leiming Li, Juliet Edwena Juel
  • Patent number: 8653012
    Abstract: Solid, particulate dicarboxylic acids may be fluid loss control agents and/or viscosifying agents for viscoelastic surfactant (VES) fluids in treatments such as well completion or stimulation in hydrocarbon recovery operations. The fluid loss control agents may include, but not be limited to, dodecanedioic acid, undecanedioic acid, decanedioic acid, azelaic acid, suberic acid, and mixtures thereof having a mesh size of from about 20 mesh to about 400 mesh (about 841 to about 38 microns). A mutual solvent or a blend of at least two alcohols subsequently added to the aqueous viscoelastic surfactant treating fluid will at least partially dissolve the solid, particulate dicarboxylic acid fluid loss control agents, and optionally also “break” or reduce the viscosity of the aqueous viscoelastic surfactant treating fluid.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: February 18, 2014
    Assignee: Baker Hughes Incorporated
    Inventor: Tianping Huang
  • Patent number: 8653013
    Abstract: A railgun which has a conductive lubricant and system of delivery reduces the electrical resistance and friction of the armature-rail sliding contact, thereby decreasing the amount of heat generated at the electrical contact. The conductive lubricant may be a ternary alloy of bismuth, indium and tin. The system of delivery for the conductive lubricant may include a plurality of surface reservoirs formed in either the rail surface, the armature face, or both.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: February 18, 2014
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventor: Peter Yaw-Ming Hsieh
  • Patent number: 8653014
    Abstract: A shampoo composition having from about 5% to about 50% of a combination of sodium lauryl sulfate and sodium laureth-n sulfate, less than 3.82% of sodium laureth-n sulfate having n>1. The shampoo composition further includes from about 0.5% to about 3% of a co-surfactant selected from the group consisting of amphoteric, zwitterionic, and nonionic surfactants. The shampoo composition has a dispersed gel network phase having at least 0.05% of one or more fatty alcohols, at least 0.01% of one or more secondary surfactants, and water. The shampoo composition further includes at least about 20% of an aqueous carrier. The shampoo composition further has an enthalpy of transition from about 0 J/g to about 0.2 J/g as measured according to differential scanning calorimetry in a peak melt transition temperature range between about 18° C. to about 30° C.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: February 18, 2014
    Assignee: The Procter & Gamble Company
    Inventors: Jennifer Elaine Hilvert, Stephanie Marie Harris Riley, Elizabeth Rebecca Aistrup
  • Patent number: 8653015
    Abstract: A solvent blend cleaner useful for reflux cleaning of chemical manufacturing equipment, including that used in manufacturing pharmaceuticals, comprises a blend of environmentally friendly and safe solvents selected on the basis of specific criteria, such as vapor pressure, vapor density, boiling point, specific heat, and heat of vaporization, among other things; achieves excellent cleaning even upon further dilution with water; and avoids the disadvantages associated with the use of conventional commodity solvents in reflux cleaning methods. Desired solvency, cleaning and wetting properties of the inventive formulations in use can be achieved through blending of solvents having the selected criteria. Additives, such as surfactants, can be added to enhance cleaning and lower solvent requirements.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: February 18, 2014
    Assignee: American Sterilizer Company
    Inventors: Shahin Shahin Keller, Nancy E. Kaiser
  • Patent number: 8653016
    Abstract: The present invention provides a biodegradable cleaning composition that includes a surfactant component including an ethoxylated 2-propyl heptanol, a chelating component including a tri-sodium salt of methylglycinediacetic acid and an emulsifier component including an ethoxylated hexanol having the formula C6H13O(CH2CH2O)H. The ethoxylated 2-propyl heptanol has the formula C5H11CH(C3H7)CH2O(C2H4O)pH, wherein p is a number of from 3 to 6. The composition also includes water and an acid component to establish a pH of the composition at less than 2. The composition is substantially free of solvents thereby reducing emission of volatile organic compounds and reducing potential environmental pollution and health hazards. The composition is also effective in removing rust, lime soap, and metal salts of fatty acids from hard surfaces including metal, vinyl, and fiberglass.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: February 18, 2014
    Assignee: BASF SE
    Inventors: Suzanne Gessner, Charles Kerobo, Sonia Patterson
  • Patent number: 8653017
    Abstract: A portable cleaning article includes a coated capsule and cleaning agent, in which the cleaning agent is contained within the coated capsule, the characteristic in that: the coated capsule having a thin-film layer and an oil layer that is coated over the surface of the thin-film layer to form a portable cleaning article. When the coated capsule is brought into contact with water by the user, the coated capsule dissolves in water for the cleaning agent to exert its cleaning function.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: February 18, 2014
    Inventor: Yun-Chun Lo
  • Patent number: 8653018
    Abstract: A surfactant concentrate is provided that includes C8-C22 acyl amido compounds, a polyol and C8-C22 fatty acids. The concentrate is formed via an interesterification reaction between a C1-C3 alkyl ester of a C8-C22 fatty acid and an amino compound or salt thereof in a polyol. The resultant surfactant concentrate will have a Hunter Lab Color Scale value L ranging from 70 to 100.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: February 18, 2014
    Assignee: Conopco, Inc.
    Inventors: Bijan Harichian, Van Au, Badreddine Ahtchi-Ali, John Robert Winters, Peter Anthony Divone, Sr.
  • Patent number: 8653019
    Abstract: A stain remover which comprises a copolymer made from as essential ingredients (a) a polymerizable monomer having a polyfluoroalkyl group with less than 8 carbon atoms and represented by the general formula H2C?CXCOO—Y—Rf and (b) a fluorine-free polymerizable monomer represented by the following general formula: H2C?CXCOO—(RO)n—X. The stain remover is effective in minimizing the amount of an organic solvent to be used. It imparts to a substrate the excellent property of removing stains therefrom and a satisfactory texture.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: February 18, 2014
    Assignee: Daikin Industries, Ltd.
    Inventors: Fumihiko Yamaguchi, Masashi Nanri, Kazunori Hayashi
  • Patent number: 8653020
    Abstract: The present invention relates in one embodiment to PAPP-A exosite(s) interactors such as antibodies which bind to a region comprising LNR3 of PAPP-A and efficiently inhibit proteolysis of IGFBP-4, but not -5. The region comprising LNR3 represents a substrate binding exosite, which can be targeted for selective proteolytic inhibition. Accordingly, the present invention relates in one embodiment to differential inhibition of natural protease substrates by exosite targeting.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: February 18, 2014
    Assignee: Aarhus Universitet
    Inventors: Claus Oxvig, Jakob Hauge Mikkelsen, Claus Gyrup Nielsen
  • Patent number: 8653021
    Abstract: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: February 18, 2014
    Assignee: Phigenix, Inc.
    Inventor: Carlton D. Donald
  • Patent number: 8653022
    Abstract: The present disclosure relates, in one aspect, to use of ghrelin splice variant or an analogue thereof for the preparation of a medicament for one or more of: treatment and/or prevention of hypercholesterolemia and/or high cholesterol and/or high cholesterol complication and/or lipemia and/or lipemia complication and/or CHD and/or weight management and/or diabetes and/or hyperglycemia.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: February 18, 2014
    Inventor: Liat Mintz
  • Patent number: 8653023
    Abstract: The present invention describes novel pharmaceutical compositions and methods for treatment of diseases, disorders, or conditions characterized by dopamine deficiency, including Alzheimer's disease, Parkinson's disease, Tourette's syndrome, schizophrenia, Huntington's disease, symptoms of attention deficit hyperactivity disorder, drug abuse and clinical depression. The treatment of the present invention utilizes PKCd inhibitors that have the dual benefit of increasing the levels of dopamine in the central nervous system while also protecting neuronal cells from neurodegeneration.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: February 18, 2014
    Assignee: Iowa State University Research Foundation, Inc.
    Inventor: Anumantha G. Kanthasamy
  • Patent number: 8653024
    Abstract: Provided is treatment of urinary tract infections including bladder infections caused by uropathogenic bacterial strains such as for example Escherichia coli with a beta-hairpin antimicrobial Arenicin polypeptide derived from the murine polychaeta Arenicola marina. Also provided are variants of Arenicin for treatment of urinary tract infections.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: February 18, 2014
    Assignee: Adenium Biotech Aps
    Inventors: Birgitte Thue Ravn, Karoline Sidelmann Brinch, Dorthe Hoej Sandvang, Hans-Henrik Kristensen Hoegenhaug, Dorotea Raventos Segura, Soeren Neve
  • Patent number: 8653025
    Abstract: The present invention discloses the structure, preparation methods and uses of a series of novel polyheterocyclic based compounds (Ia-Ib and IIa-IIb) that are highly effective for inhibiting hepatitis C virus (HCV): where the structural variables are defined herein. The present invention is also provides a method of treating HCV infection by the polyheterocyclic based HCV inhibitory compounds, compositions and therapeutic methods.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: February 18, 2014
    Assignee: AB Pharma Ltd.
    Inventor: Zheng-Yun James Zhan
  • Patent number: 8653026
    Abstract: Methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY-720 or an analog are described.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: February 18, 2014
    Inventor: Zhonigman Ma
  • Patent number: 8653027
    Abstract: The present invention is based on the discovery that Humanin and humanin analogues protect pancreatic beta cells in vitro and in vivo from apoptosis. Accordingly, humanin and its analogues are useful for preventing and treating diabetes and promoting beta cell survival in a number of applications.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: February 18, 2014
    Assignee: The Regents of the University of California
    Inventors: Pinchas Cohen, Kuk-Wha Lee
  • Patent number: 8653028
    Abstract: The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.
    Type: Grant
    Filed: May 1, 2006
    Date of Patent: February 18, 2014
    Inventors: Rui Rong Yuan, Wei Ping Li, Yasuhiro Maeda, Peter Dowling
  • Patent number: 8653029
    Abstract: The present invention provides a composition that may be used as an implant or a bone graft substitute or extender for filling voids and/or promoting fusion of osseous tissues. The implant may comprise ceramic granules such as calcium phosphate granules and one or more polysaccharide excipients, and may be in the form of a putty or flowable paste. Optionally, the implant may also comprise a growth factor such as a bone morphogenetic protein.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: February 18, 2014
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Scott Mitchell Vickers, Jeffrey L. Scifert
  • Patent number: 8653030
    Abstract: A formulation containing a biologically active compound having a chemical structure with hydrogen bonding sites, a first biocompatible, hydrolytically degrading polycarbonate with hydrogen bonding sites and tyrosine-derived diphenol monomer units, and a second biocompatible hydrolytically degrading polymer that is less hydrophobic than the polycarbonate, wherein the second polymer degrades hydrolytically to form acidic degradation products that promote the release of the active compound. Methods for active compound delivery are also disclosed.
    Type: Grant
    Filed: January 7, 2008
    Date of Patent: February 18, 2014
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Joachim B. Kohn, Deborah M. Schachter
  • Patent number: 8653031
    Abstract: We describe preparation of compounds of an AT1 receptor antagonist(s) and Angiotensin (1-7), for example, Angiotensin-(1-7) losartanate and analogues thereof, and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products. Cyclodextrins and derivatives thereof may be used for the micro-encapsulation of compounds, for example, Angiotensin (1-7) losartanate, liposomes and biodegradable polymers and/or mixtures of these systems and/or derivative products for the obtainment of nano- or microparticles as controlled or sustained release devices of Ang-(1-7) losartanate and analogues and/or mixtures thereof. The compounds may be used as agents for treating or preventing hypertension, cardiovascular diseases, heart hypertrophy, heart failure, coronary diseases, such as angina pectoris, endothelial disorder or endothelial lesions, as a consequence, for example, of atherosclerosis processes or in association with diabetes mellitus.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: February 18, 2014
    Assignee: Universidade Federal de Minas Gerais
    Inventors: Rubén Dario Sinisterra Millán, Cynthia Fernades Ferreira Santos, Robson Augusto Souza Dos Santos, Ivana Silva Lula, Frederico Barros De Sousa, Pedro Pires Goulart Guimaraes, Angelo Márcio Leite Denadai
  • Patent number: 8653032
    Abstract: Disclosed is a pharmaceutical composition for preventing or treating TRPV1 activity-related or inflammation-related, diseases or conditions, containing a Maillard peptide separated from well-aged traditional soy sauce as an active ingredient. The Maillard peptide in the present invention functions both as a TRPV1 agonist and a TRPV1 antagonist, and further functions as a TRPV1 activity modulator. Therefore, the Maillard peptide can be used for preventing or treating TRPV1 activity-related diseases such as pain, neurological diseases, urgent defecation, inflammatory bowel disease, respiratory diseases, urinary incontinence, overactive bladder, neurogenic / allergic / inflammatory skin diseases, skin, eye or mucosal irritation, hyperacusis, tinnitus, vestibular hypersensitivity, heart disease, etc.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: February 18, 2014
    Assignees: Korea Food Research Institute, SNU R & DB Foundation
    Inventors: Mee-Ra Rhyu, Ah-Young Song, Eun-Young Kim, Seog Bae Oh, YoungJoo Lee, Won Chung Lim
  • Patent number: 8653033
    Abstract: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: February 18, 2014
    Assignee: Jazz Pharmaceuticals International Limited
    Inventors: David J. Ellis, George P. Miljanich, David E. Shields
  • Patent number: 8653034
    Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: February 18, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Jin He
  • Patent number: 8653035
    Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: February 18, 2014
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffan Walter, Harpreet Singh
  • Patent number: 8653036
    Abstract: The present invention relates to methods of treating retinitis pigmentosa using ?-turn peptidomimetic cyclic compounds or derivatives thereof. The ?-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs useful in treating retinitis pigmentosa.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: February 18, 2014
    Assignee: Mimetogen Pharmaceuticals Inc.
    Inventors: Garth Cumberlidge, Horacio U. Saragovi, Karen Meerovitch
  • Patent number: 8653037
    Abstract: This invention provides novel truncation mutants of a phytochrome from the bacterium Deinococcus radiodurans. When expressed either in bacteria or mammalian cells, these mutant phytochromes spontaneously incorporate biliverdin, a ubiquitous intermediate in heme catabolism, and become fluorescent in the infrared (IR) region. These phytochromes are the first genetically encoded labels that can be excited by far-red light and fluorescent in the true IR (>700 nm). If these mutants instead incorporate protoporphyrin IX, an intermediate in heme biosynthesis, illumination now generates significant amounts of singlet oxygen. Singlet oxygen is useful because it can be used to kill individual proteins or cells, detect long-range protein-protein interactions, or generate electron-microscopic contrast. The invention also relates to methods of making and using such proteins and protein variants.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: February 18, 2014
    Assignees: The Centre National de la Recherche Scientifique, The Regents of the University of California
    Inventors: Xiaokun Shu, Antoine Royant, Roger Tsien
  • Patent number: 8653038
    Abstract: An HLA-A*1101-restricted WT1 peptide, specifically, a peptide comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein, wherein the peptide has an ability to bind to an HLA-A*1101 molecule, and has an ability to induce a CTL is described. A peptide dimer having an ability to bind to an HLA-A*1101 molecule and having an ability to induce a CTL, in which two peptide monomers each comprising an amino acid sequence cons sting of 9 contiguous amino acids from a WT1 protein and comprising at least one cysteine residue are bound to each other through a disulfide bond is also described. Furthermore, a polynucleotide encoding the peptide, a pharmaceutical composition for the treatment and/or prevention of a cancer comprising the same and the like are provided.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: February 18, 2014
    Assignee: International Institute of Cancer Immunology, Inc.
    Inventor: Haruo Sugiyama
  • Patent number: 8653039
    Abstract: Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: February 18, 2014
    Inventors: Robert J. Hickey, Linda H. Malkas
  • Patent number: 8653040
    Abstract: The purpose of the present invention is to provide a means of enhancing the bodily absorption of sesamin-class compounds. By using sesamin-class compounds and quercetin glycosides in combination, the bodily absorption of the sesamin-class compounds can be enhanced.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: February 18, 2014
    Assignee: Suntory Holdings Limited
    Inventors: Namino Tomimori, Yoshiko Ono
  • Patent number: 8653041
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein Q1 and Q2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: February 18, 2014
    Assignee: Achaogen, Inc.
    Inventors: Adam Aaron Goldblum, Paola Dozzo, Timothy Robert Kane, James Bradley Aggen, Martin Sheringham Linsell, Darin James Hildebrandt, Micah James Gliedt
  • Patent number: 8653042
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: February 18, 2014
    Assignee: Achaogen, Inc.
    Inventors: Paola Dozzo, Adam Aaron Goldblum, James Bradley Aggen, Martin Sheringham Linsell
  • Patent number: 8653043
    Abstract: Using neoglycosylation, the impact of differential glycosylation upon the divergent anticancer and anti-HIV properties of the triterpenoid betulinic acid (BA) was examined. Each member from a library of 37 differentially glycosylated BA variants was tested for anticancer and anti-HIV activities. Enhanced analogs for both desired activities were discovered with the corresponding antitumor or antiviral enhancements diverging, based upon the appended sugar, into two distinct compound subsets.
    Type: Grant
    Filed: January 7, 2010
    Date of Patent: February 18, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Randal D. Goff, Jon Scott Thorson
  • Patent number: 8653044
    Abstract: The invention provides anti-apoptotic agents and therapies and uses thereof. Specifically, the anti-apoptotic agents and therapies involve human Xist gene, Xist RNA, Xist gene product, and antagonists and small molecule mimics of these nucleic acids and proteins.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: February 18, 2014
    Assignee: University of Southern California
    Inventor: John Tower
  • Patent number: 8653045
    Abstract: Dual suppression of the MAP kinase and PI3K/Akt pathways showed synergistic or greatly enhanced anti-melanoma cell effects, compared to suppression of a single pathway, including the inhibition of cell proliferation, transformation and invasion, induction of G0/G1 cell cycle arrest and, importantly, cell apoptosis. Remarkably, suppression of either pathway induces the expression of thyroid iodide-handling genes and dual suppression of the two pathways synergistically and robustly induces expression of these genes, accompanied by uptake of radioiodine in the cells. These genes include sodium/iodide symporter, thyroid-stimulating hormone receptor, thyroglobulin, thyroperoxidase, pendrin gene, thyroid transcription factors (e.g., TTF-1, TTF-2, PAX8) and other thyroid genes.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: February 18, 2014
    Assignee: The Johns Hopkins University
    Inventor: Michael Mingzhao Xing
  • Patent number: 8653046
    Abstract: The invention relates to the use of a skin permeating compound such as phloretin for controlling transgene expression under control of the Pseudomonas putida DOT-T1E-derived bacterial repressor TtgR, to a vector comprising the genetic code for the repressor TtgR fused to a transactivation or a transrepressor domain, to a vector comprising a TtgR-specific operator sequence (OTtgR), a promoter and a polynucleotide coding for an endogenous or exogenous protein, and to a mammalian cell transiently or constitutively transfected with the mentioned vectors, and to mammals comprising such cells in nano- or microcontainers.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: February 18, 2014
    Assignee: ETH Zurich
    Inventors: Martin Fussenegger, Marc Gitzinger
  • Patent number: 8653047
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: February 18, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Richard Lee
  • Patent number: 8653048
    Abstract: Prodrugs based on gemcitabine structure shown in formula (I) as well as their synthetic method and application are disclosed in the present invention, wherein the definitions for the groups of a, b, c, d, E, Z and V are described in the specification. By modifying the N4 group, the solubility, the bioavailability and the organ specificity of the prodrugs are improved. Therefore, the fast metabolism problem is overcome for the produced prodrugs compounds. Intestinal toxicity induced by gemcitabine is decreased. Thereby, the prodrugs can be delivered by oral administration in clinics and further improve their anti-tumor, anti-cancer, anti-infection and diffusion preventing capability, and can also specifically act on liver or colon. The synthetic method is simple and adapted to industrial production.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: February 18, 2014
    Assignee: Sanlugen Pharmatech Ltd.
    Inventors: Xiaoxia Xue, Gang Li, Changjun Sun, Wenbao Li
  • Patent number: 8653049
    Abstract: The invention provides a compound (which can act as an adjuvant) of Formula I or Formula (II), wherein R1 R4 R5 R6 and R7 are each independently selected from hydrogen, acetyl, hydrocarbyl, a lipid moiety and a lipid acyl moiety; R2 is a hydroxyl, a hydrocarbyl, a lipid moiety, a lipid acyl moiety; or an amino hydrocarbyl group optionally substituted with a hydrocarbyl, a lipid moiety or a lipid acyl moiety; R3 and R8 are each independently selected from acetyl, a hydrocarbyl, a lipid moiety and a lipid acyl moiety; X is a peptide chain; The above normuramylglycopeptide compounds can be located in liposomes and micelles and can function as immunomodulators, along with a desired antigen (or DNA encloding the antigen), in (e.g. DNA) vaccines.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: February 18, 2014
    Assignees: Imuthes Limited, Institute of Organic Chemistry and Biochemistry AV CR, V.V.I., Vyzkumny USTAV Veterinarniho Lekarstvi, V.V.I.
    Inventors: Karsten Hipler, Andrew Miller, Jaroslav Turanek, Miroslav Ledvina
  • Patent number: 8653050
    Abstract: The present invention relates to novel phenyl bicyclic methyl amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: February 18, 2014
    Assignee: Allergan, Inc.
    Inventors: Janet A. Takeuchi, Ling Li, Wha-Bin Im
  • Patent number: 8653051
    Abstract: The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of 3-alpha-androstanediol, preferably in combination with a type 5 phosphodiesterase (PDE5) inhibitor.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: February 18, 2014
    Assignee: Emotional Brain B.V.
    Inventors: Jan Johan Adriaan Tuiten, Johannes Martinus Maria Bloemers, Robertus Petrus Johannes De Lange
  • Patent number: 8653052
    Abstract: The present invention is a product comprising a ?2 agonist and a progestin, as a combined preparation for separate, simultaneous or sequential use in the treatment or prevention of muscle loss. The present invention is also a ?2 agonist selected from R,R-formoterol, indacaterol or ritodrine, for use in the treatment or prevention of muscle loss.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: February 18, 2014
    Assignee: Acacia Pharma Limited
    Inventors: Julian Clive Gilbert, Robert William Gristwood
  • Patent number: 8653053
    Abstract: A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: February 18, 2014
    Assignee: Galderma S.A.
    Inventors: Nancy Puglia, Jerry Roth, Rosario Ramirez
  • Patent number: 8653054
    Abstract: Novel chemical agents are described herein. More specifically, 2-(N-substituted piperazinyl) pregnane and 2-(N-substituted piperazinyl) androstane derivatives exhibiting cytotoxicity on a variety of cancer cell lines are disclosed herein.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: February 18, 2014
    Assignee: Universite Laval
    Inventors: Donald Poirier, Jenny Roy, Rene Maltais
  • Patent number: 8653055
    Abstract: The invention provides novel compositions of water-insoluble corticosteroid drug in combination with antimicrobial agents and very low concentrations of polymers and surfactants for topical, otic and ophthalmic treatment. The invention provides stable aqueous suspension where the ingredients remain in such a state so as to allow for immediate re-suspension, when desired, even after extended periods of settling. The invention provides also a method for treating inflammation with low systemic absorption and side-effects of the corticosteroid.
    Type: Grant
    Filed: September 15, 2005
    Date of Patent: February 18, 2014
    Assignee: Teva Animal Health, Inc.
    Inventors: Richard K. Farng, Chung-Tsin Chiu, Ba Cuong Tu, Kenneth W. Kwochka